Drug Profile
Follitropin alfa sustained-release - Alkermes/Serono
Alternative Names: Follitropin alfa-ProLease formulation - Alkermes/Serono; GONAL-f® micoencapsulated; Microencapsulated follitropin alfa; Microencapsulated rhFSH; ProLease® formulation rhFSHLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Merck Serono
- Developer Alkermes
- Class Follicle stimulating hormones; Infertility therapies; Peptide fragments; Pituitary gonadotropins; Recombinant proteins
- Mechanism of Action Ovarian follicle stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Female infertility; Male infertility
Most Recent Events
- 30 Oct 2004 Discontinued - Phase-I for Female infertility in USA (SC)
- 30 Oct 2004 Discontinued - Phase-I for Male infertility in USA (SC)
- 24 Sep 2002 Phase-I clinical trials in Female infertility in USA (SC)